Phibro Q3 Beats; Sales, Earnings Grow Double Digits; Guidance Maintained

What happened

Phibro Animal Health reported Q3 FY2026 net sales of $383.5 million, up 10% YoY, and net income of $24.0 million, up 15%. The results align with the company's updated guidance for FY2026 sales of $1.43–$1.48 billion and Adjusted EBITDA of $230–$240 million. The performance reflects continued strength in the Animal Health segment, partly benefiting from the Zoetis acquisition. However, the company still faces significant leverage (net debt/EBITDA ~4.7x) and unresolved regulatory risk from carbadox (Mecadox), which represents ~$20–22 million in annual sales. While Q3 execution is encouraging, the risk/reward remains balanced given the valuation at ~25x P/E and elevated leverage.

Implication

The Q3 results reinforce management's ability to execute on the Zoetis acquisition and drive growth, keeping the FY2026 guidance achievable. However, with the stock trading at ~25x P/E and net debt/EBITDA at 4.7x, the margin of safety is thin. Investors should watch for margin expansion and de-leveraging progress as catalysts for a more constructive view. The unresolved carbadox issue remains a key risk that could derail earnings if resolved unfavorably. Until these factors improve, the HOLD stance is appropriate.

Thesis delta

Q3 results show strong execution with 10% sales growth and 15% earnings growth, aligning with guidance and supporting the current HOLD thesis. The key shift is that near-term operational risk appears lower, but the structural issues of leverage and carbadox remain unresolved, so the thesis does not warrant an upgrade yet. This quarter's performance buys time but does not eliminate the need for de-leveraging and regulatory clarity.